35 results on '"Bhella, Sita"'
Search Results
2. Very late relapse in Hodgkin lymphoma: Characterizing an understudied population
3. Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
4. Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective.
5. Implementation of a Social Work-Led Advance Care Planning Clinic for CAR T-Cell Therapy Patients
6. Covid-19 Vaccine Immunogenicity and Safety Surrounding Fourth and Subsequent Vaccine Doses in Patients with Hematologic Malignancies
7. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study
8. An online educational module to improve general internal medicine trainees' knowledge and comfort in managing acute complications of sickle cell disease
9. An Online Educational Module to Improve General Internal Medicine Trainees' Knowledge and Comfort in Managing Acute Complications of Sickle Cell Disease.
10. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
11. Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study
12. Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study
13. Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience
14. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
15. Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma
16. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma
17. High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-Line Bendamustine Rituximab and Rituximab Maintenance
18. IBCL-550 High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-line Bendamustine Rituximab and Rituximab Maintenance
19. Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study
20. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF +/−plerixafor vs cyclophosphamide/ GCSF +/−plerixafor
21. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume
22. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains
23. Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume
24. Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size
25. Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma
26. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
27. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/−plerixafor vs cyclophosphamide/GCSF+/−plerixafor.
28. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.
29. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
30. Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant
31. Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study
32. Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response
33. Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study
34. Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial
35. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.